• small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

2015 News Releases

Webcast ImageWebcast
MIMEDX GROUP INC at Canaccord Musculoskeletal  (Replay)
Mar 24, 2015 at 10:00 a.m. PT
MIMEDX GROUP INC at Canaccord Musculoskeletal
Tuesday, March 24, 2015 10:00 a.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
MIMEDX GROUP INC at Regen Med Investor Day (Replay)
Mar 25, 2015 at 8:00 a.m. ET
MIMEDX GROUP INC at Regen Med Investor Day
Wednesday, March 25, 2015 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
Mar 23, 2015Government Declines to Intervene in Action Against MiMedx
MARIETTA, Ga., March 23, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it has received notice from the Department of Justice that it has declined at this time to intervene in the qui tam action that... 
Printer Friendly Version
Mar 17, 2015MiMedx to Present at 3rd Annual Regen Med Investor Day
MARIETTA, Ga., March 17, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Deborah Dean, Executive Vice President, and Frank Burrows, Vice President, will represent the Company at the 3rd Annual Regen M... 
Printer Friendly Version
Mar 16, 2015MiMedx To Present At Canaccord's 10th Annual Musculoskeletal Conference
THE COMPANY TO EXHIBIT AT THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF ORTHOPAEDIC SURGEONS (AAOS) MARIETTA, Ga., March 16, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at C... 
Printer Friendly Version
Feb 26, 2015MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit
Company Records Revenue of $118.2 million, Operating income of $7.1 million and Net Income of $6.2 million MARIETTA, Ga., Feb. 26, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record results for ... 
Printer Friendly Version
Feb 04, 2015MiMedx Announces Release Date For 2014 Full Year Results
MARIETTA, Ga., Feb. 4, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its results for the fourth quarter and year ended December 31, 2014, will be released before the opening of the market on Thursda... 
Printer Friendly Version
Feb 03, 2015MiMedx Withdraws Complaint Against Organogenesis Without Prejudice To Focus On Investigation
MARIETTA, Ga., Feb. 3, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced that it has voluntarily withdrawn its tortious interference lawsuit against Organogenesis, Inc., without prejudice.  MiMedx has expressly re... 
Printer Friendly Version
Jan 12, 2015MiMedx Announces over 30 National Account Contracts
CONTRACTS COVER MORE THAN 4,000 U.S. HOSPITALS MARIETTA, Ga., Jan. 12, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that the status of the Company's National Account contracts with Group Purchasing O... 
Printer Friendly Version
Jan 12, 2015MiMedx Exceeds Fourth Quarter And Full Year 2014 Revenue Forecasts
$118.2 MILLION FULL YEAR 2014 REVENUE IS DOUBLE 2013 AND $39.6 MILLION Q4 2014 REVENUE IS 120% INCREASE OVER Q4 2013 MARIETTA, Ga., Jan. 12, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record re... 
Printer Friendly Version
Jan 06, 2015MiMedx Announces $10 Million Increase to Stock Repurchase Program
MARIETTA, Ga., Jan. 6, 2015 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its Board of Directors increased the Company's authorization for its share repurchase plan from $10,000,000 to $20,000,000.  The $20,... 
Printer Friendly Version

Products

CONTACT US

888.543.1917